dc.contributor.author |
Veiga, Viviane C. |
|
dc.contributor.author |
Prats, João A. G. G. |
|
dc.contributor.author |
Farias, Danielle L. C. |
|
dc.contributor.author |
Rosa, Regis G. |
|
dc.contributor.author |
Dourado, Leticia K. |
|
dc.contributor.author |
Zampieri, Fernando G. |
|
dc.contributor.author |
Machado, Flávia R. |
|
dc.contributor.author |
Lopes, Renato D. |
|
dc.contributor.author |
Berwanger, Otavio |
|
dc.contributor.author |
Azevedo, Luciano C. P. |
|
dc.contributor.author |
Avezum, Álvaro |
|
dc.contributor.author |
Lisboa, Thiago |
|
dc.contributor.author |
Rojas, Salomón S. O. |
|
dc.contributor.author |
Coelho, Juliana C. |
|
dc.contributor.author |
Leite, Rodrigo T. |
|
dc.contributor.author |
Carvalho, Júlio C. |
|
dc.contributor.author |
Andrade, Luis E. C. |
|
dc.contributor.author |
Sandes, Alex F. |
|
dc.contributor.author |
Pintão, Maria C. T. |
|
dc.contributor.author |
Castro Junior, Claudio G. |
|
dc.contributor.author |
Santos, Sueli V. |
|
dc.contributor.author |
de Almeida, Thiago M. L. |
|
dc.contributor.author |
Costa, André N. |
|
dc.contributor.author |
Gebara, Otávio C. E. |
|
dc.contributor.author |
Freitas, Flávio G. Rezende de |
|
dc.contributor.author |
Pacheco, Eduardo S. |
|
dc.contributor.author |
Machado, David J. B. |
|
dc.contributor.author |
Martin, Josiane |
|
dc.contributor.author |
Conceição, Fábio G. |
|
dc.contributor.author |
Siqueira, Suellen R. R. |
|
dc.contributor.author |
Damiani, Lucas P. |
|
dc.contributor.author |
Ishihara, Luciana M. |
|
dc.contributor.author |
Schneider, Daniel |
|
dc.contributor.author |
Souza, Denise de |
|
dc.contributor.author |
Cavalcanti, Alexandre B. |
|
dc.contributor.author |
Scheinberg, Phillip |
|
dc.date.accessioned |
2021-07-08T19:57:41Z |
|
dc.date.available |
2021-07-08T19:57:41Z |
|
dc.date.issued |
2021 |
|
dc.identifier.citation |
VEIGA, V. C. et al. Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial. BMJ, v. 372, n. 84, jun. 2021. Disponível em: http://hdl.handle.net/11690/1780. Acesso em: 08 jul. 2021. |
pt_BR |
dc.identifier.uri |
http://hdl.handle.net/11690/1780 |
|
dc.language.iso |
en_US |
pt_BR |
dc.publisher |
BMJ Publishing Group |
pt_BR |
dc.rights |
Open Access |
en |
dc.subject |
COVID-19 |
pt_BR |
dc.title |
Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial |
pt_BR |
dc.type |
Artigo |
pt_BR |